Intelgenx Technologies (Intelgenx Technologies) Effective Interest Rate on Debt % : 14.69% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Intelgenx Technologies Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Intelgenx Technologies's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was $2.28 Mil. Intelgenx Technologies's average total debt for the quarter that ended in Dec. 2023 was $15.52 Mil. Therefore, Intelgenx Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 14.69%.

Intelgenx Technologies Effective Interest Rate on Debt % Historical Data

The historical data trend for Intelgenx Technologies's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intelgenx Technologies Effective Interest Rate on Debt % Chart

Intelgenx Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

14.42

12.85

13.92

11.66

12.49

Intelgenx Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															8.30	10.35	9.77	10.50	14.69

Competitive Comparison of Intelgenx Technologies's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Intelgenx Technologies's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intelgenx Technologies's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intelgenx Technologies's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Intelgenx Technologies's Effective Interest Rate on Debt % falls into.

Intelgenx Technologies Effective Interest Rate on Debt % Calculation

Intelgenx Technologies's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Dec. 2022 )	+	Total Debt (A: Dec. 2023 ))	/ count )
=	-1 * -1.625	/	( (10.511	+	15.501)	/ 2 )
=	-1 * -1.625	/	13.006
=	12.49 %

where

	Total Debt (A: Dec. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	10.239	+	0.272
=	10.511

	Total Debt (A: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	12.106	+	3.395
=	15.501

Intelgenx Technologies's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: Sep. 2023 )	+	Total Debt (Q: Dec. 2023 ))	/ count )
=	-1 * -2.28	/	( (15.535	+	15.501)	/ 2 )
=	-1 * -2.28	/	15.518
=	14.69 %

where

	Total Debt (Q: Sep. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	15.203	+	0.332
=	15.535

	Total Debt (Q: Dec. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	12.106	+	3.395
=	15.501

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

Intelgenx Technologies (OTCPK:IGXT) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

Intelgenx Technologies Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Intelgenx Technologies's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

Intelgenx Technologies (Intelgenx Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intelgenx Technologies Corp (OTCPK:IGXT) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

0IL:Germany IGX:Canada

Address

6420 Abrams, Ville Saint Laurent, QC, CAN, H4S 1Y2

Website

https://www.intelgenx.com

Intelgenx Technologies Corp is an oral drug delivery company. The company is focused on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Intelegenx focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing. Its geographical segments are Europe, Canada, and United States.

Executives

Atai Life Sciences Ag	10 percent owner	KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v.	10 percent owner	524 BROADWAY, NEW YORK NY 10013
Karen Kalayajian	officer: VP, Finance&Admin - Subsidiary	4896 RUE EDOUARD-BRUNETTE, LAVAL A8 H7T 0J4
Dwight Gorham	officer: CEO	15B BARKLEY ST, ARNPRIOR A6 K7S 3G8
David Kideckel	officer: SVP, Corp. Dev&SA - Subsidiary	23 PEVERIL HILL SOUTH, TORONTO, ON A6 M6C 3A7
Horst G Zerbe	10 percent owner, officer: Chief Executive Officer	714 MAIN ROAD, HUDSON A8 JOP1H0
Andre Godin	officer: CFO	440 DES CARMANTINES, LAVAL A8 H7X 0B6
Tommy Kenny	officer: VP IP,Lgl Affairs - Subsidiary	88 CH. DES SAULES, ST-ADOLPHE D' HOWARD A8 J0T 2B0
Dana Matzen	officer: VP Business+Corp. Development	4771 RUE SHERBROOKE O., WESTMOUNT A8 H3Z1G5
Ingrid Zerbe	10 percent owner, officer: Corporate Secretary	714 MAIN ROAD, HUDSON A8 J0P1H0
Rodolphe Obeid	officer: Vice President, Operations	4779 RUE VILLERET, PIERREFOND A8 H9K1P6
Bernard Boudreau	director	2 TURNMILL DR., HALIFAX A5 B3M4H2
John Edward Durham	officer: Vice President Manufacturing	102 MAYFAIR, HUDSON A8 J0P1H0
Mark Nawacki	director	118 ARLINGTON AVENUE, WESTMOUNT A8 H3Y2W4
Robert J. Bechard	officer: VP Corporate Development	141 EASTON AVENUE, MONTREAL WEST A8 H4X 1L4